GnRH agonists and add‐back therapy: is there a perfect combination?

Andrew Pickersgill, A Pickersgill, Pickersgill A
British journal of obstetrics and gynaecology · 1998 · vol. 105(5) , pp. 475–485 · doi:10.1111/j.1471-0528.1998.tb10146.x · PMID:9637115 · W2092687039
review OA: closed CC0 ⤵ 21 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-14 ⓘ

This review explores the optimal combination of GnRH agonists and add-back therapy for managing endometriosis, discussing current evidence and future directions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Adult Endometriosis Endometriosis Estrogen Replacement Therapy Female Follicle Stimulating Hormone Follicle Stimulating Hormone Gonadotropin-Releasing Hormone Humans Hyperandrogenism Hyperandrogenism Leiomyoma Leiomyoma Lipoproteins, HDL Lipoproteins, HDL Lipoproteins, LDL Lipoproteins, LDL Luteinizing Hormone Luteinizing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (21)

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK